Pegylated interferon alfa-2b is a treatment for hepatitis C developed by Schering-Plough brand name is PegIntron.It was approved in January 2001.It has also been approved as treatment for melanoma with nodal involvement after surgical resection under the brand name Sylatron by Merck in April 2011.PEG-interferon alpha is a pegylated interferon composed of 165 amino acids.
This page contains content from the copyrighted Wikipedia article "Peginterferon alfa-2b"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.